As of 2025-09-17, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -1.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 96.81 mil USD. INO's TTM EBITDA according to its financial statements is -96.02 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 15.6x | 14.5x |
| Forward P/E multiples | 19.1x - 38.9x | 29.0x |
| Fair Price | (34.05) - (27.73) | (38.84) |
| Upside | -1593.6% - -1316.2% | -1803.6% |
| Date | EV/EBITDA |
| 2025-09-12 | -1.06 |
| 2025-09-11 | -1.21 |
| 2025-09-10 | -1.21 |
| 2025-09-09 | -1.27 |
| 2025-09-08 | -1.33 |
| 2025-09-05 | -1.29 |
| 2025-09-04 | -1.27 |
| 2025-09-03 | -1.25 |
| 2025-09-02 | -1.17 |
| 2025-08-29 | -1.06 |
| 2025-08-28 | -1.11 |
| 2025-08-27 | -1.11 |
| 2025-08-26 | -0.88 |
| 2025-08-25 | -0.83 |
| 2025-08-22 | -0.83 |
| 2025-08-21 | -0.80 |
| 2025-08-20 | -0.77 |
| 2025-08-19 | -0.82 |
| 2025-08-18 | -0.80 |
| 2025-08-15 | -0.78 |
| 2025-08-14 | -0.64 |
| 2025-08-13 | -0.69 |
| 2025-08-12 | -0.57 |
| 2025-08-11 | -0.54 |
| 2025-08-08 | -0.53 |
| 2025-08-07 | -0.54 |
| 2025-08-06 | -0.55 |
| 2025-08-05 | -0.57 |
| 2025-08-04 | -0.56 |
| 2025-08-01 | -0.54 |
| 2025-07-31 | -0.53 |
| 2025-07-30 | -0.54 |
| 2025-07-29 | -0.54 |
| 2025-07-28 | -0.57 |
| 2025-07-25 | -0.56 |
| 2025-07-24 | -0.58 |
| 2025-07-23 | -0.61 |
| 2025-07-22 | -0.55 |
| 2025-07-21 | -0.53 |
| 2025-07-18 | -0.52 |
| 2025-07-17 | -0.50 |
| 2025-07-16 | -0.49 |
| 2025-07-15 | -0.47 |
| 2025-07-14 | -0.50 |
| 2025-07-11 | -0.50 |
| 2025-07-10 | -0.52 |
| 2025-07-09 | -0.55 |
| 2025-07-08 | -0.49 |
| 2025-07-07 | -0.48 |
| 2025-07-03 | -0.48 |